Top

Tag: ALTUVIIIO


FDA, Regulations

FDA Approves Sanofi’s Once-weekly ALTUVIIIO for Hemophilia A

February 24, 2023

Via: Contract Pharma

The U.S. FDA has approved Sanofi’s ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy. ALTUVIIIO is indicated for routine prophylaxis and on-demand treatment to control bleeding episodes, as […]